Author + information
- Received April 5, 2007
- Revision received June 11, 2007
- Accepted June 18, 2007
- Published online October 2, 2007.
- Marie-Claude Morice, MD, FACC, FESC⁎,⁎ (, )
- Patrick W. Serruys, MD, PhD, FACC†,
- Paul Barragan, MD‡,
- Christoph Bode, MD§,
- Gerrit-Anne Van Es, PhD∥,
- Hans-Peter Stoll, MD¶,
- David Snead, PhD#,
- Laura Mauri, MD, MSc, FACC⁎⁎,
- Donald E. Cutlip, MD, FACC⁎⁎ and
- Eduardo Sousa, MD, PhD, FACC††
- ↵⁎Reprint requests and correspondence:
Dr. Marie-Claude Morice, Institut Hospitalier Jacques Cartier, Avenue du Noyer Lambert, 91300 Massy, France.
Objectives This study examined the clinical outcomes at 5 years in RAVEL (A Randomized Comparison of a Sirolimus-Eluting Stent With a Standard Stent for Coronary Revascularization), the first controlled trial of drug-eluting stents.
Background The 6-month rate of angiographic coronary restenosis has been markedly lowered by sirolimus-eluting stents (SES). The long-term performance of drug-eluting stents, however, is under close scrutiny.
Methods The trial included 238 patients (mean age 60.7 ± 10.4 years, 76% men) with a single, de novo native coronary artery lesion, randomly assigned to treatment with SES versus bare-metal stents (BMS). Rates of major adverse cardiac events (MACE), defined as all-cause mortality, myocardial infarction, and percutaneous or surgical revascularization up to 5 years of follow-up, and rates of stent thrombosis were compared between the 2 treatment groups.
Results Complete datasets were available in 92.5% of patients treated with SES and 89.1% of patients assigned to BMS. The 1-, 3-, and 5-year rates of survival free from target lesion revascularization (TLR) were, respectively, 99.2%, 93.8%, and 89.7% in the SES group versus 75.9%, 75.0%, and 74.0% in the control group (p < 0.001; log-rank). Rates of all MACE at 5 years were 25.8% in patients treated with SES versus 35.2% in patients assigned to BMS (p = 0.03; log-rank). Rates of stent thrombosis, per protocol or by the Academic Research Consortium definitions, were similar in both groups.
Conclusions The 5-year rate of TLR associated with SES was significantly lower than that with BMS. There was no apparent adverse effect associated with the use of SES, although the trial was not powered to examine uncommon complications.
This study was sponsored by Cordis Corporation (a Johnson & Johnson Company), Clinical Research Europe, Belgium, and Warren, New Jersey.
- Received April 5, 2007.
- Revision received June 11, 2007.
- Accepted June 18, 2007.
- American College of Cardiology Foundation